 |
 |
Bivalirudin |
| |
Bivalirudin is a 20-residue oligopeptide whose structure combines a carboxy-terminal region that recognizes thrombin’s fibrinogen binding site, and an amino terminal tetrapeptide that inhibits the active site of thrombin, connected by a tetraglycine spacer.
Bivalirudin is used as an anti-coagulant, in combination with aspirin, in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty. It is used as a therapeutic agent for the treatment of, and prevention of platelet-associated ischemic disorders.
Bivalirudin is produced using a method based on solid-phase peptide synthesis technology. The crude material thus produced is purified by RP-HPLC and characterized by amino acid analysis, N-terminal sequencing, NMR, MALDI-TOF, LC-MS, ion chromatography and platelet aggregation assay for biological activity. The indigenously developed Bivalirudin is marketed in the Indian market under the brand name `Gioloc’.
Disclaimer: Products under patents are offered
for sale only in those countries where patents have expired. |
|
|
|
|
